MX2013002268A - Metodos para detectar anticuerpos anti-he4 y metodos de diagnosis y/o de prognosis de condiciones asociadas con celulas que expresan he4. - Google Patents
Metodos para detectar anticuerpos anti-he4 y metodos de diagnosis y/o de prognosis de condiciones asociadas con celulas que expresan he4.Info
- Publication number
- MX2013002268A MX2013002268A MX2013002268A MX2013002268A MX2013002268A MX 2013002268 A MX2013002268 A MX 2013002268A MX 2013002268 A MX2013002268 A MX 2013002268A MX 2013002268 A MX2013002268 A MX 2013002268A MX 2013002268 A MX2013002268 A MX 2013002268A
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies
- biological sample
- amount
- sequence
- cancer
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 83
- 238000003745 diagnosis Methods 0.000 title abstract description 8
- 238000004393 prognosis Methods 0.000 title description 8
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 100
- 206010033128 Ovarian cancer Diseases 0.000 claims abstract description 69
- 239000012472 biological sample Substances 0.000 claims abstract description 69
- 206010061535 Ovarian neoplasm Diseases 0.000 claims abstract description 64
- 238000011282 treatment Methods 0.000 claims abstract description 52
- 238000001514 detection method Methods 0.000 claims abstract description 16
- 210000004881 tumor cell Anatomy 0.000 claims abstract description 10
- 238000012544 monitoring process Methods 0.000 claims abstract description 5
- 241000282414 Homo sapiens Species 0.000 claims description 70
- 201000011510 cancer Diseases 0.000 claims description 48
- 210000004027 cell Anatomy 0.000 claims description 41
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 38
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 37
- 229920001184 polypeptide Polymers 0.000 claims description 33
- 210000002966 serum Anatomy 0.000 claims description 30
- 150000001413 amino acids Chemical class 0.000 claims description 26
- 238000003556 assay Methods 0.000 claims description 22
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 20
- 239000002773 nucleotide Substances 0.000 claims description 20
- 125000003729 nucleotide group Chemical group 0.000 claims description 20
- 239000000523 sample Substances 0.000 claims description 16
- 238000001356 surgical procedure Methods 0.000 claims description 14
- 230000001225 therapeutic effect Effects 0.000 claims description 14
- 108091033319 polynucleotide Proteins 0.000 claims description 13
- 102000040430 polynucleotide Human genes 0.000 claims description 13
- 230000027455 binding Effects 0.000 claims description 12
- 210000002381 plasma Anatomy 0.000 claims description 12
- 239000002157 polynucleotide Substances 0.000 claims description 12
- 239000003153 chemical reaction reagent Substances 0.000 claims description 11
- 239000012530 fluid Substances 0.000 claims description 9
- 239000013060 biological fluid Substances 0.000 claims description 8
- 210000004369 blood Anatomy 0.000 claims description 7
- 239000008280 blood Substances 0.000 claims description 7
- 239000013642 negative control Substances 0.000 claims description 7
- 210000002700 urine Anatomy 0.000 claims description 6
- 238000002560 therapeutic procedure Methods 0.000 claims description 5
- 206010036790 Productive cough Diseases 0.000 claims description 4
- 210000003567 ascitic fluid Anatomy 0.000 claims description 4
- 238000001415 gene therapy Methods 0.000 claims description 4
- 210000004910 pleural fluid Anatomy 0.000 claims description 4
- 230000004044 response Effects 0.000 claims description 4
- 210000003296 saliva Anatomy 0.000 claims description 4
- 210000003802 sputum Anatomy 0.000 claims description 4
- 208000024794 sputum Diseases 0.000 claims description 4
- 210000001138 tear Anatomy 0.000 claims description 4
- 229940022399 cancer vaccine Drugs 0.000 claims description 3
- 238000009566 cancer vaccine Methods 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 238000011476 stem cell transplantation Methods 0.000 claims description 3
- 238000011156 evaluation Methods 0.000 claims description 2
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 4
- 229960002685 biotin Drugs 0.000 claims 2
- 235000020958 biotin Nutrition 0.000 claims 2
- 239000011616 biotin Substances 0.000 claims 2
- 108090001008 Avidin Proteins 0.000 claims 1
- 108010090804 Streptavidin Proteins 0.000 claims 1
- 238000009175 antibody therapy Methods 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 238000006911 enzymatic reaction Methods 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
- 101000955067 Homo sapiens WAP four-disulfide core domain protein 2 Proteins 0.000 abstract description 5
- 239000000203 mixture Substances 0.000 abstract description 2
- 108090000623 proteins and genes Proteins 0.000 description 43
- 235000018102 proteins Nutrition 0.000 description 38
- 102000004169 proteins and genes Human genes 0.000 description 38
- 239000012634 fragment Substances 0.000 description 28
- 239000000427 antigen Substances 0.000 description 26
- 102000036639 antigens Human genes 0.000 description 25
- 108091007433 antigens Proteins 0.000 description 25
- 238000012286 ELISA Assay Methods 0.000 description 21
- 238000002965 ELISA Methods 0.000 description 16
- 235000001014 amino acid Nutrition 0.000 description 15
- 201000010099 disease Diseases 0.000 description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 238000012360 testing method Methods 0.000 description 15
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 14
- 239000002299 complementary DNA Substances 0.000 description 12
- 208000024891 symptom Diseases 0.000 description 10
- 239000003550 marker Substances 0.000 description 9
- 210000001672 ovary Anatomy 0.000 description 9
- 239000013612 plasmid Substances 0.000 description 9
- 238000011534 incubation Methods 0.000 description 8
- 238000012123 point-of-care testing Methods 0.000 description 8
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 210000004379 membrane Anatomy 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 150000007523 nucleic acids Chemical class 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 101710193132 Pre-hexon-linking protein VIII Proteins 0.000 description 6
- 238000010367 cloning Methods 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 101710132601 Capsid protein Proteins 0.000 description 5
- 101150074155 DHFR gene Proteins 0.000 description 5
- 206010027476 Metastases Diseases 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- 238000002512 chemotherapy Methods 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 201000010063 epididymitis Diseases 0.000 description 5
- 102000037865 fusion proteins Human genes 0.000 description 5
- 108020001507 fusion proteins Proteins 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 230000009401 metastasis Effects 0.000 description 5
- 210000004197 pelvis Anatomy 0.000 description 5
- 230000009257 reactivity Effects 0.000 description 5
- 101710094648 Coat protein Proteins 0.000 description 4
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 4
- 101710125418 Major capsid protein Proteins 0.000 description 4
- 101710141454 Nucleoprotein Proteins 0.000 description 4
- 101710083689 Probable capsid protein Proteins 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000001574 biopsy Methods 0.000 description 4
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 4
- 239000007943 implant Substances 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 210000003101 oviduct Anatomy 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 241000607479 Yersinia pestis Species 0.000 description 3
- 230000004520 agglutination Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 210000004748 cultured cell Anatomy 0.000 description 3
- 210000000918 epididymis Anatomy 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 102000052147 human WFDC2 Human genes 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 238000011275 oncology therapy Methods 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 230000002611 ovarian Effects 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 238000009163 protein therapy Methods 0.000 description 3
- 238000003127 radioimmunoassay Methods 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 210000004291 uterus Anatomy 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- AWGBKZRMLNVLAF-UHFFFAOYSA-N 3,5-dibromo-n,2-dihydroxybenzamide Chemical compound ONC(=O)C1=CC(Br)=CC(Br)=C1O AWGBKZRMLNVLAF-UHFFFAOYSA-N 0.000 description 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 2
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108010022394 Threonine synthase Proteins 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 208000020560 abdominal swelling Diseases 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000002820 assay format Methods 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 102000004419 dihydrofolate reductase Human genes 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001839 endoscopy Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 201000005249 lung adenocarcinoma Diseases 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 210000002747 omentum Anatomy 0.000 description 2
- 238000009806 oophorectomy Methods 0.000 description 2
- 239000013610 patient sample Substances 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 239000004417 polycarbonate Substances 0.000 description 2
- 229920000515 polycarbonate Polymers 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 208000025444 tumor of salivary gland Diseases 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 1
- URLOWBXNQIYFHV-UHFFFAOYSA-N 6-aminohexanoic acid;1-hydroxypyrrolidine-2,5-dione Chemical compound ON1C(=O)CCC1=O.NCCCCCC(O)=O URLOWBXNQIYFHV-UHFFFAOYSA-N 0.000 description 1
- 241001156002 Anthonomus pomorum Species 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- CTCHDPAJHVDPRN-UHFFFAOYSA-N Integrin Natural products C=1C(OC)=CC(O)=C(C(C=2CC=C(C)C)=O)C=1OC=2C1=CC=C(O)C=C1O CTCHDPAJHVDPRN-UHFFFAOYSA-N 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102100038297 Kallikrein-1 Human genes 0.000 description 1
- 101710176219 Kallikrein-1 Proteins 0.000 description 1
- BFVQTKQTUCQRPI-YYEZTRBPSA-N LPS with O-antigen Chemical compound O([C@@H]1[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@@H]4[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]5[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O5)O)O4)O)[C@@H](O)[C@@H](CO)O3)NC(C)=O)[C@@H](O)[C@@H](CO[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)NC(C)=O)O2)NC(C)=O)[C@H](O)[C@@H](CO)OC1O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)OC([C@@H]1O)O[C@H]1[C@H](O)[C@@H]([C@@H](O)COC2[C@H]([C@@H](O)[C@H](OP(O)(O)=O)[C@@H]([C@@H](O)CO)O2)O)OC([C@H]1O)O[C@H]1[C@H](OP(O)(=O)OP(O)(=O)OCCN)[C@@H]([C@@H](O)CO)OC([C@H]1O)O[C@H]1[C@H](O[C@]2(O[C@@H]([C@@H](O)[C@H](O[C@]3(O[C@@H]([C@@H](O)[C@H](OP(O)(=O)OCCN)C3)[C@@H](O)CO)C(O)=O)C2)[C@@H](O)CO)C(O)=O)C[C@](O[C@@H]1[C@@H](O)CO)(OC[C@H]1O[C@@H](OC[C@@H]2[C@H]([C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O2)O)[C@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@H]([C@@H]1OP(O)(O)=O)OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)C(O)=O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O BFVQTKQTUCQRPI-YYEZTRBPSA-N 0.000 description 1
- 102000019298 Lipocalin Human genes 0.000 description 1
- 108050006654 Lipocalin Proteins 0.000 description 1
- 102000013519 Lipocalin-2 Human genes 0.000 description 1
- 108010051335 Lipocalin-2 Proteins 0.000 description 1
- 206010027459 Metastases to lymph nodes Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 239000012124 Opti-MEM Substances 0.000 description 1
- 102000052812 Ornithine decarboxylases Human genes 0.000 description 1
- 108700005126 Ornithine decarboxylases Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000004264 Osteopontin Human genes 0.000 description 1
- 108010081689 Osteopontin Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 102100029500 Prostasin Human genes 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 241000656145 Thyrsites atun Species 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 206010046910 Vaginal haemorrhage Diseases 0.000 description 1
- 102000050760 Vitamin D-binding protein Human genes 0.000 description 1
- 101710179590 Vitamin D-binding protein Proteins 0.000 description 1
- 102000021095 WAP Four-Disulfide Core Domain Protein 2 Human genes 0.000 description 1
- 108091002660 WAP Four-Disulfide Core Domain Protein 2 Proteins 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000002435 cytoreductive effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000001687 destabilization Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000009585 enzyme analysis Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000009802 hysterectomy Methods 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000003317 immunochromatography Methods 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 210000000565 lesser omentum Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 208000030427 mucinous ovarian cancer Diseases 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 108010055837 phosphocarrier protein HPr Proteins 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 150000003057 platinum Chemical class 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 108010031970 prostasin Proteins 0.000 description 1
- 238000002331 protein detection Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- -1 rectal pressure Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 238000013391 scatchard analysis Methods 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 238000009589 serological test Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 238000011539 total abdominal hysterectomy Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000009808 unilateral salpingo-oophorectomy Methods 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 206010046901 vaginal discharge Diseases 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57449—Specifically defined cancers of ovaries
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37738710P | 2010-08-26 | 2010-08-26 | |
| PCT/US2011/049274 WO2012027631A2 (en) | 2010-08-26 | 2011-08-26 | Methods for detecting anti-he4 antibodies and methods of diagnosis and/or prognosis of conditions associated with he4-expressing cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2013002268A true MX2013002268A (es) | 2014-02-03 |
Family
ID=45724080
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013002268A MX2013002268A (es) | 2010-08-26 | 2011-08-26 | Metodos para detectar anticuerpos anti-he4 y metodos de diagnosis y/o de prognosis de condiciones asociadas con celulas que expresan he4. |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20130224772A1 (enExample) |
| EP (1) | EP2609429B1 (enExample) |
| JP (1) | JP6097688B2 (enExample) |
| CN (1) | CN103180732B (enExample) |
| AU (1) | AU2011293217A1 (enExample) |
| BR (1) | BR112013004458A2 (enExample) |
| CA (1) | CA2809368C (enExample) |
| MX (1) | MX2013002268A (enExample) |
| RU (1) | RU2600891C2 (enExample) |
| WO (1) | WO2012027631A2 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7270960B2 (en) * | 2001-08-29 | 2007-09-18 | Pacific Northwest Research Institute | Diagnosis of ovarian carcinomas |
| CA2827618C (en) * | 2011-02-17 | 2019-08-06 | Fujirebio Diagnostics, Inc. | Compositions and methods of use for the determination of he4a |
| CN103424551B (zh) * | 2013-08-06 | 2015-08-26 | 江苏福隆生物技术有限公司 | 人附睾上皮分泌蛋白4定量测定试剂盒及其检测方法 |
| US10267802B2 (en) * | 2015-09-23 | 2019-04-23 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of prognosis and diagnosis of ovarian cancer |
| KR102599695B1 (ko) * | 2015-12-17 | 2023-11-07 | 에프. 호프만-라 로슈 아게 | 마커 사람 부고환 단백질 4 (he4) 기반의 폐 선암 재발의 발견 방법 및 관련 용도 |
| CN109280084B (zh) * | 2018-03-09 | 2022-04-29 | 河南大学 | 一种胶体硒标记的抗he4抗体、试剂盒及其制备方法 |
| CN109480771B (zh) * | 2018-10-17 | 2021-09-07 | 江西惠肽生物科技有限公司 | 一种卵巢肿块良恶的确定方法及确定装置 |
| CN110895279B (zh) * | 2019-11-27 | 2023-02-28 | 普健生物（武汉）科技有限公司 | 一种检测人附睾分泌蛋白4的化学发光试剂盒 |
| WO2022204017A1 (en) * | 2021-03-22 | 2022-09-29 | Curative Inc. | Immunization assessments using saliva or nasal specimen |
| CN113045663B (zh) * | 2021-04-18 | 2022-04-01 | 深圳市国创纳米抗体技术有限公司 | 一种抗he4的纳米抗体1a8及其应用 |
| CN117487018B (zh) * | 2023-09-27 | 2024-05-17 | 武汉爱博泰克生物科技有限公司 | 抗人附睾分泌蛋白4的兔单克隆抗体及其应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5017342A (en) * | 1988-06-01 | 1991-05-21 | Ortho Diagnostic Systems Inc. | Device for immunoassay determinations |
| AU2002241720A1 (en) * | 2000-11-08 | 2002-06-18 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer |
| US7270960B2 (en) * | 2001-08-29 | 2007-09-18 | Pacific Northwest Research Institute | Diagnosis of ovarian carcinomas |
| US20040142325A1 (en) * | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| EP1924710B1 (en) * | 2005-09-15 | 2011-03-30 | Val-Chum, S.E.C. | Methods of diagnosing ovarian cancer |
| EP2982761B1 (en) * | 2006-01-04 | 2017-10-04 | Fujirebio America, Inc. | Use of he4 and other biochemical markers for assessment of endometrial and uterine cancers |
| AU2007297310B2 (en) * | 2006-09-13 | 2013-11-07 | Oncimmune Limited | Improved immunoassay methods |
| KR20100015438A (ko) * | 2007-03-09 | 2010-02-12 | 트리패스 이미징, 인코포레이티드 | Ｈｅ4 모노클로날 항체 및 이의 사용 방법 |
| EP2126577B1 (en) * | 2007-03-29 | 2013-03-13 | Fujirebio Diagnostics, Inc. | Use of he4 for assessment of breast cancers |
| WO2010061393A1 (en) * | 2008-11-30 | 2010-06-03 | Compugen Ltd. | He4 variant nucleotide and amino acid sequences, and methods of use thereof |
| CN101525614A (zh) * | 2009-04-13 | 2009-09-09 | 大连美亿德生物科技有限公司 | 人卵巢癌肿瘤标志物he4酶联免疫诊断试剂盒 |
-
2011
- 2011-08-26 CA CA2809368A patent/CA2809368C/en active Active
- 2011-08-26 CN CN201180051336.5A patent/CN103180732B/zh active Active
- 2011-08-26 US US13/818,466 patent/US20130224772A1/en not_active Abandoned
- 2011-08-26 AU AU2011293217A patent/AU2011293217A1/en not_active Abandoned
- 2011-08-26 WO PCT/US2011/049274 patent/WO2012027631A2/en not_active Ceased
- 2011-08-26 BR BR112013004458A patent/BR112013004458A2/pt not_active IP Right Cessation
- 2011-08-26 JP JP2013526167A patent/JP6097688B2/ja active Active
- 2011-08-26 RU RU2013113314/15A patent/RU2600891C2/ru active
- 2011-08-26 MX MX2013002268A patent/MX2013002268A/es unknown
- 2011-08-26 EP EP11820697.8A patent/EP2609429B1/en active Active
-
2018
- 2018-01-25 US US15/879,963 patent/US20180217158A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2011293217A1 (en) | 2013-04-11 |
| JP6097688B2 (ja) | 2017-03-15 |
| JP2013536442A (ja) | 2013-09-19 |
| EP2609429A2 (en) | 2013-07-03 |
| CN103180732A (zh) | 2013-06-26 |
| CN103180732B (zh) | 2017-09-08 |
| CA2809368C (en) | 2021-08-24 |
| US20180217158A1 (en) | 2018-08-02 |
| EP2609429B1 (en) | 2017-09-20 |
| CA2809368A1 (en) | 2012-03-01 |
| WO2012027631A3 (en) | 2012-07-19 |
| RU2600891C2 (ru) | 2016-10-27 |
| BR112013004458A2 (pt) | 2016-06-07 |
| WO2012027631A2 (en) | 2012-03-01 |
| RU2013113314A (ru) | 2014-10-10 |
| EP2609429A4 (en) | 2014-03-19 |
| US20130224772A1 (en) | 2013-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103180732B (zh) | 检测抗he4抗体的方法以及诊断和/或预后与he4表达细胞相关的病症的方法 | |
| JP5711196B2 (ja) | 卵巣癌を判定するためのｈｅ４及び他の生化学マーカーの使用 | |
| US20030232399A1 (en) | Cancer detection methods and reagents | |
| JP2010520768A (ja) | Ｈｅ４モノクローナル抗体およびそれらの使用方法 | |
| EP2403880A1 (en) | Matrix metalloproteinase-7 (mmp-7) monoclonal antibodies and methods for their use in the detection of ovarian cancer | |
| CN107110848B (zh) | 以脱氧羟腐胺缩赖氨酸合酶基因作为指标使用的动脉硬化及癌的检测方法 | |
| JP5144742B2 (ja) | 乳がんの評価のためのｈｅ４の使用 | |
| US20090042224A1 (en) | Methods for diagnosis and/or prognosis of ovarian cancer | |
| JP2008035836A (ja) | 腫瘍マーカー | |
| JP2021117117A (ja) | 前立腺癌のバイオマーカー及び該バイオマーカーを用いた前立腺癌を検出するための方法並びに診断キット | |
| HK1187100B (en) | Methods for detecting anti-he4 antibodies and methods of diagnosis and/or prognosis of conditions associated with he4-expressing cells | |
| HK1187100A (en) | Methods for detecting anti-he4 antibodies and methods of diagnosis and/or prognosis of conditions associated with he4-expressing cells | |
| HK1225411B (en) | Use of he4 and other biochemical markers for assessment of ovarian cancers | |
| HK1225411A (en) | Use of he4 and other biochemical markers for assessment of ovarian cancers | |
| HK1225411A1 (en) | Use of he4 and other biochemical markers for assessment of ovarian cancers | |
| HK1166109A (en) | Use of he4 and other biochemical markers for assessment of ovarian cancers | |
| HK1219514B (en) | Use of he4 and other biochemical markers for assessment of endometrial and uterine cancers |